Drugs / KAI-1678
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01135108 | Mar 2009 → Mar 2010 | spinal cord injury | KAI Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01106716 | Mar 2009 → Mar 2010 | postherpetic neuralgia | KAI Pharmaceuticals | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01015235 Comparator | Dec 2008 → Feb 2010 | — | KAI Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KAI-1678 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01015235 ↗ |
| Known as | KP-1678 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297775 ↗ |
| Action | Inhibit | “Protein kinase C epsilon inhibitor” CHEMBL4297775 ↗ |
| Route | Subcutaneous | “Subcutaneous infusion-once over 4 hours” NCT01015235 ↗ |
| Target | PRKCE | “Protein kinase C epsilon inhibitor” CHEMBL4297775 ↗ |